Several lines of evidence suggest that some cellular effectors may display a dynamic regulation of Rad51 expression in prostate cancers, including p53, Cdk4 and mitogen-activated protein kinase (MAPK) (35–38). The gene discussed is WNK2; the disease is prostate carcinoma.